Source:http://linkedlifedata.com/resource/pubmed/id/17656367
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
41
|
pubmed:dateCreated |
2007-10-8
|
pubmed:abstractText |
The divergent response and the molecular mechanisms underlying the anti-cancer effects of retinoid X receptor (RXR) ligand (rexinoid) therapy are poorly understood. This study demonstrates that ligand-activated RXR homodimer facilitated G(1) arrest by up-regulation of p21 in vitro and in vivo but failed to induce G(1) arrest when p21 expression was blocked by p21 small interfering RNA. RXR ligand-dependent p21 up-regulation was transcriptionally controlled through the direct binding of RXR homodimers to two consecutive retinoid X response elements in the p21 promoter. Structural overlap of a retinoic acid response element with these retinoid X response elements led to a high affinity binding of retinoic acid receptor/RXR heterodimer to the retinoic acid response element, resulting in the prevention of RXR ligand-mediated p21 transactivation. These data show that p21 is a potential and novel molecular target for RXR ligand-mediated anti-cancer therapy and that the expression level of retinoic acid receptor and RXR in tumors may be crucial to induce p21-mediated cell growth arrest in RXR ligand therapy.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/CDKN1A protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin-Dependent Kinase Inhibitor...,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Retinoic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Retinoid X Receptors
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0021-9258
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
12
|
pubmed:volume |
282
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
29987-97
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:17656367-Animals,
pubmed-meshheading:17656367-Cell Cycle,
pubmed-meshheading:17656367-Cell Line, Tumor,
pubmed-meshheading:17656367-Cercopithecus aethiops,
pubmed-meshheading:17656367-Cyclin-Dependent Kinase Inhibitor p21,
pubmed-meshheading:17656367-Dimerization,
pubmed-meshheading:17656367-Female,
pubmed-meshheading:17656367-Humans,
pubmed-meshheading:17656367-Mice,
pubmed-meshheading:17656367-Mice, Nude,
pubmed-meshheading:17656367-Neoplasm Transplantation,
pubmed-meshheading:17656367-Protein Binding,
pubmed-meshheading:17656367-Receptors, Retinoic Acid,
pubmed-meshheading:17656367-Retinoid X Receptors,
pubmed-meshheading:17656367-Transcription, Genetic,
pubmed-meshheading:17656367-Transcriptional Activation
|
pubmed:year |
2007
|
pubmed:articleTitle |
p21WAF1/CIP1 is a common transcriptional target of retinoid receptors: pleiotropic regulatory mechanism through retinoic acid receptor (RAR)/retinoid X receptor (RXR) heterodimer and RXR/RXR homodimer.
|
pubmed:affiliation |
NCI, National Institutes of Health, Bethesda, Maryland 20892-4255, USA. Takemi.Tanaka@uth.tmc.edu
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Intramural
|